A new recombinant pituitary adenylate cyclase-activating polypeptide (PACAP)-derived peptide, MPAPO, which has higher stability and PAC1-specific potency, was generated. The actions of MPAPO on corneal wound repairing and lacrimal secretion were examined.
P
ituitary adenylate cyclase-activating polypeptide (PACAP) is one of the important neuropolypeptides and a new member in the secretin/glucagon/vasoactive intestinal peptide (VIP) family. 1 Pituitary adenylate cyclase-activating polypeptide is present in two forms, PACAP38 and PACAP27 in vivo, and has 60% homology with VIP, but the capacity of PACAP for stimulating brain pituicytes to generate adenylate cyclase is 1000-fold that of VIP. 2 The biological actions of PACAP are mediated through three G protein-coupled receptors, namely, PAC1, VPAC1, and VPAC2. PAC1 is the specific 7-transmembrane receptor and exhibits high affinity for PACAP, but much lower affinity for VIP. VPAC1 and VPAC2 receptors display similar affinity for PACAP and VIP. 3 In mammals, PAC1 and VPAC receptors are expressed in the nervous, gastrointestinal, reproductive, and immune systems. However, PAC1 is mainly expressed in endocrine glands, such as the pituitary and adrenal, in the eye, and in the peripheral nervous system (PNS). In the PNS, especially in many ganglia and axons, PAC1 receptor distribution is significantly higher than that of VPAC receptor. 4, 5 A growing body of evidence suggests that PACAP can efficiently promote traumatic brain or nerve injury repair and nerve synapse growth and modulate the function of the immune system. 6, 7 Pituitary adenylate cyclase-activating polypeptide was strongly upregulated in injured neurons, including motor, sympathetic, and sensory neurons. 8, 9 Pituitary adenylate cyclase-activating polypeptide-deficient (knockout, KO) mice exhibited delayed axonal regeneration in a facial nerve crush model, and PACAP administration in vivo can attenuate axon degeneration in central nervous system (CNS) injury models. 10, 11 In PACAP KO mice, exogenous PACAP treatment appeared to reduce neuronal damage resulting from a lack of endogenous PACAP expression and afforded a degree of extra protection, equivalent to that observed with the wild mice.
progenitor cells via Ca 2þ -dependent signaling pathways through PAC1. 14 Therefore, PACAP or a PAC1-specific agonist has been proposed as a potential agent for injury repair.
However, the therapeutic application of PACAP or some PAC1-specific agonist has been hampered by their poor stability and limited bioavailability in vivo. 15, 16 Particularly, PACAP is susceptible to protease degradation by dipeptidyl peptidase-4 (DPP4), which causes loss of the first two Nterminal amino acids (H-S) required for receptor activation. 17 Furthermore, the 17th amino acid is methionine (M) and prone to oxidation, thereby leading to the destabilization and low bioavailability of this peptide. Many approaches have been explored to improve its pharmacokinetics, including PEGylation, coadministration of peptide-degrading enzyme inhibitors, and various delivery systems. [18] [19] [20] However, success in these strategies has been limited by the propensity of the large polymers to interfere with peptide function. In the current study, we have developed the novel recombinant DPP4-resistant peptide MPAPO with 29 amino acids by gene recombination technique. Compared with PACAP27, a methionine (M) and a lycine (K) was respectively added at the N-and C-terminus of MPAPO; in addition, we have introduced two mutations (M17L, L27K) into the peptide MPAPO, so as to increase its stability by eliminating oxidation and DPP4 degradation and also improve its potency to activate PAC1 receptor. Thus the in vitro stability of recombinant MPAPO was approximately 31-fold higher than that of PACAP and VIP. MPAPO can significantly promote the proliferation of mouse corneal epithelium cells and synapse growth of trigeminal ganglion cells. Our in vivo studies demonstrated that MPAPO can quickly perform mouse corneal epithelial wound repair due to its high stability and bioavailability. Furthermore, MPAPO exhibits potent effects in increasing lacrimal fluid and protein secretion and inhibiting corneal neovascularization, which is one significant side effect caused by some growth factor therapeutics.
MATERIALS AND METHODS

Animals
C57BL/6 mice and Japanese white rabbits were purchased from Southern Medical University, Guangzhou. All experiments conformed to the use of Laboratory Animals and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Laboratory Animal Ethics Committee of Jinan University, China.
Bioinformatics Analysis
The amino acid sequence of human PAC1 receptor (hPAC1) was obtained from the databank in the National Center for Biotechnology Information (NCBI; Bethesda, MD, USA) (NP_001186564.1). Locations of the extracellular N-terminal domain and the transmembrane domain in the sequence of PAC1 receptor were predicted. The protein BLAST program against Protein Data Bank (PDB) available at NCBI was used to select a template structure for homology modeling. From the selected template (PDB entry 2JOD), a three-dimensional model of MPAPO was obtained by MODELER module in Discovery Studio 2.5.5 (Accelrys, San Diego, CA, USA). The extracellular domain of hPAC1 was modeled through homology modeling by using the structure of hPAC1-Rs (PDB entry 2JOD) as a template, and the transmembrane domain of hPAC1 was modeled by using the known structure of rhodopsin (PDB entry 1U19) as a template. 21 The PROCHECK program (Accelrys) was then applied to check the stereochemical quality of the model, and the Ramachandran plot produced by PROCHECK indicated that 91.2% of residues in the obtained model were in the most favored regions. Choosing the top score structure for modeling, molecular dynamics (MD) simulations were performed.
Protein-protein docking studies were conducted using an initial-stage rigid-body docking algorithm, ZDOCK, and a refinement procedure, RDOCK. The docking of hPAC1 homology model with MPAPO was performed by using the ZDOCK module in Discovery Studio 2.5.5. ZDOCK was run with a 68 rotational sampling grid and the default 1.2-Å grid step size. A total of 54,000 poses were sampled, and the top 1000 poses were saved. According to the binding interface, ZDOCK results were filtered. The RDOCK refinement procedure was used to perform CHARMM minimization on the top 20 poses of the filtered ZDOCK output, and the poses were reranked on the basis of the RDOCK empirical free energy scoring function.
Preparation and Identification of the Recombinant Peptide MPAPO
The MPAPO gene was designed according to the bias of Escherichia coli for the codons to ensure its high expression. The gene was synthesized and amplified in two steps as described previously 22 using three oligonucleotide primers: F1: 5 0 -GGT GGT CATATG CAT AGC GAT GGC ATT TTT ACC GAT AGC TAT AGC-3 0 , containing an NdeI site (underlined); F2: 5 0 -TTT TTT CAC CGC CAG CTG TTT GCG ATA GCG GCT ATA  GCT ATC GGT-3  0 ; F3: 5  0 -CCACCATGCTCTTCCGCA TTT TTT  CAC CGC CGC CAG ATA TTT TTT CAC CGC CAG-3 0 , containing a SapI site (underlined); GGTGGT at the 5 0 end of F1 and CCACCA at the 5 0 end of F3 are the protecting bases. After polymerase chain reaction (PCR), the products were purified by the PCR cleanup kit (Qiagen, Hilden, Germany) and digested with NdeI and SapI; the DNA fragment was directly ligated to pKYB-MCS vector (NEB, Ipswich, MA, USA) to yield the expression plasmid pKYB-MPAPO. MPAPO gene in plasmid pKYB-MPAPO was verified by DNA sequencing. The vector pKY-MPAPO was transformed into E. coli ER2566 and the fusion proteins were expressed and purified by the optimized procedure previously described. 23 After chitin bead (NEB) affinity chromatography purification for the cell lysate, MPAPO was purified and prepared by reverse-phase high-performance liquid chromatography (HPLC) using 4.6-3 150-mm 300 SB-C18 Sep-Pak column (Agilent Technologies, Beijing, China) through gradient elution of acetonitrile from 3% to 60% for 20 minutes at 0.5 mL/min. The eluate containing MPAPO was dried by lyophilization. Prepared MPAPO was identified by tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis (tricine-SDS-PAGE) and 4000 Q TRAP electrospray ionization mass spectrometry (ESI-MS) (Applied Biosystems, Foster City, CA, USA).
14 The purity of MPAPO was assayed by HPLC method.
Stability Assay
MPAPO, PACAP27, PACAP38, or VIP was respectively dissolved in sodium phosphate buffer (20 mM, pH 8.0) containing 150 mM sodium chloride to obtain a solution at a final concentration of 1 mg/mL and then incubated at 378C. Samples were analyzed by liquid chromatography mass spectrometry (LC-MS; Applied Biosystems, Foster City, CA, USA) at 1-, 2-, 3-, and 4-week time points (after incubation). The HPLC-ESI-MS system containing 1.0-3 150-mm 300 SB-C18 Sep-Pak column was used to analyze each sample after an injection of 2 lL through increasing concentrations of acetonitrile from 5% to 55% for 35 minutes at 0.05 mL/min.
Competition Receptor Binding Assay
The potential of MPAPO to displace [ 125 I]PACAP27 by competitively binding to the human PAC1 receptor was examined in PAC1-CHO cell membrane by the method previously described. 23 The half-maximal inhibitory concentration (IC50) of MPAPO, PACAP27, PACAP38, and VIP was detected. [K15,R16,L27]VIP(1-7)/GRF(8-27), a VPAC1-specific agonist, was used as the negative control in the receptor binding assay. 24 Assay of Cyclic Adenosine Monophosphate (cAMP) Accumulation Induced by MPAPO PAC1-CHO, VPAC1-CHO, and VPAC2-CHO cells were cultured in Dulbecco's modified Eagle's medium (DMEM) at 378C and washed with PBS twice before experimentation. Pituitary adenylate cyclase-activating polypeptide 38 or MPAPO was added to 500-lL cell suspension (2 3 10 6 cells/mL) to obtain a solution at a final peptide concentration from 1 3 10 À11 to 1 3 10 À6 M, and the solutions were incubated at 378C for 5 minutes. One microliter 0.2 M HCl was added and the mixtures were incubated at 378C for 30 minutes. Cyclic AMP concentrations induced by MPAPO or PACAP27 were measured by the method previously described 23 using the cAMP enzyme immunoassay kit (Cayman Chemical Company, Ann Arbor, MI, USA).
Effect of MPAPO on Corneal Wound Repairing and Trauma-Related Protein Expression
Twenty-four mice were randomly divided into four groups (six mice per group), and central corneal wounding was performed as previously described. 25 Then mice were treated with 20 lL sterile normal saline (NS, vehicle), 1 nM recombinant bovine (rb)-bFGF, PACAP27, and MPAPO solution, respectively. Mice were treated with NS or different peptides once every 6 hours. Before administration and 12, 24, 36, and 48 hours after the first administration, 1% sterile fluorescein sodium was applied to the injured corneal epithelium. After 3 seconds, ocular surfaces were rinsed with sterile saline solution and quickly photographed with a digital camera (Eastman Kodak, Rochester, NY, USA). Assessment of wound closure used fluorescein staining of the ocular surface and digital analysis of the stained area. The images were examined with the software Image-Pro Plus ver. 4.0 (Planetron, Tokyo, Japan). The corneal wound area and the repair ratio [formula: repair ratio ¼ (original wound area À wound area at each time point)/original wound area] were analyzed.
Two hundred male C57BL/6 mice were randomly divided into four groups: uninjured amd postinjured NS-, PACAP27-, and MPAPO-treated groups (50 mice per group). The method for central corneal wounding was the same as described above. Twenty microliters sterile NS, 1 nM PACAP27, and MPAPO solution were applied to the ocular surfaces once every 6 hours. Ten mice per group were euthanized at 6, 12, 24, 30, and 36 hours, respectively, after the first administration. The separated corneas were placed in precooled lysate (300 lL/ mg) and freezing-thawing was repeated three times. After the samples were homogenized by vortexing and centrifuged at 1200g for 30 minutes, the supernatant was taken and the total protein quantitation was carried out using a bicinchoninic acid (BCA) protein quantitation kit (Invitrogen, Carlsbad, CA, USA). The samples were assayed for expression change of nerve growth factor (NGF; R&D Systems, Minneapolis, MN, USA), transforming growth factor-b (TGF-b; Biovalue, Seoul, South Korea), fibronectin (FN; Biovalue), vascular endothelial growth factor (VEGF; Biovalue), and intercellular cell adhesion molecule-1 (ICAM-1; R&D Systems) at each time point using the corresponding enzyme-linked immunosorbent assay (ELISA) kit.
Effects of MPAPO on Neovascularization and Secretion of Lacrimal Fluid and Lacrimal Protein of Japanese White Rabbits
Forty-two Japanese white rabbits were divided into seven groups (six rabbits per group, female and male rabbits each half): NS and 0.2, 0.5, and 1.0 nM MPAPO and PACAP27 groups. The rabbits were subjected to topical anesthesia with 10 lL 0.4% benoxinate hydrochloride in a single eye, and Schirmer tear test was performed using standard sterile strips. One millimeter of the rounded end of the strip was folded and inserted into the lower eyelid; the strip was removed after 5 minutes, and the length of the wet portion below the folded end was immediately measured. Before administration and 10, 30, 60, and 120 minutes after administration of 50 lL NS or various concentrations of MPAPO and PACAP27 solution, the wet strip lengths were determined, and the length differences between pre-and postadministration represented the change in lacrimal secretion.
Another 42 Japanese white rabbits were grouped and treated with the same methods as explained above. The lacrimal fluids were collected into a precooled eppendorf (EP) tube with a pipetter at 10, 30, 60, and 120 minutes after administration of 50 lL NS or various concentrations of MPAPO and PACAP27 solution. The protein concentrations in each experimental group were determined with BCA protein assay kit (Invitrogen). The protein secretion ratios at each time point after administration were calculated.
Two hundred Japanese white rabbits were divided into four groups (50 rabbits per group) and treated with 50 lL NS, rbbFGF, PACAP27, and MPAPO (1 nM) solution, respectively, after alkali burn to each rabbit's right central cornea. Anesthesia in the Japanese white rabbits was induced with intramuscular injections of ketamine hydrochloride, 50 mg/kg, and chlorpromazine, 10 mg/kg. Benoxinate hydrochloride (0.4%) was used for topical anesthesia, and surplus moisture was removed with a cotton-tipped applicator. Six-millimeter filter paper discs were soaked for 3 seconds in 0.5 M NaOH solution, then applied to the central cornea for 30 seconds, resulting in the right central cornea alkali burn model. Rabbits were continuously treated for 14 days with NS or different peptides once every 8 hours. Corneal neovascularization (CNV) was examined on day 7 and 14 after administration by slit-lamp biomicroscopy (Oakland, NJ, USA), and the length of the least tortuous and longest new blood vessel that had grown into the center of the corneal opacity was defined as the length of CNV. The area of CNV was calculated using the following formula:
, where C is the circumference of CNV coverage on the cornea, l is the length of the selected vessel, and r is the radius of the rabbit cornea (r ¼ 7 mm). Corneal neovascularization inhibition was calculated according to the following formula: (average CNV area in the control group À average CNV area in the treatment group)/average CNV area in the control group. -injured trigeminal ganglion cells treated with or without MPAPO were lysed by adding Trizol reagent, and total RNA of three groups of cells was obtained using Qiagen RNeasy mini kit and Qiagen RNase-free DNase. Gene microarrays of three groups of cells were performed as described previously. 26 The normal and H 2 O 2 -injured mouse trigeminal ganglion cells treated with 1 nM MPAPO, with PBS or 1 nM PACAP27 as control, were lysed by precooled lysate (containing 5% proteinase inhibitors, 10% phosphatase inhibitors, and 1% phenylmethanesulfonyl fluoride [PMSF]), and the total protein in the supernatant was quantified with BCA protein quantitation kit. In the PAC1 blocking experiments, trigeminal ganglion cells were preincubated with 100 nM DMax for 30 minutes at 378C before adding 1 nM MPAPO. After the total protein was separated by 12% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Immobilon P; Millipore, Billerica, MA, USA), the membranes were respectively incubated with the extracellular signal-regulated protein kinases 1/2 (Erk1/2), phosphorylated Erk1/2 (p-Erk1/2), protein kinase B (Akt), and phosphorylated Akt (Thr308) [p-Akt (Thr308)] rabbit mAb (Cell Signaling Technology, Inc., Boston, MA, USA) overnight at 48C. Horseradish peroxide (HRP)-conjugated goat anti-rabbit IgG (Cell Signaling Technology, Inc.) was used as the secondary antibody. Protein bands were visualized by using an ECL kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and densitometric analysis of the Western blot results was performed with ImageJ analysis software (http://imagej.nih. gov/ij/; provided in the public domain by the National Institutes of Health, Bethesda, MD, USA).
Assay of MPAPO Affecting the Proliferation of Mouse Corneal Epithelial Cells
Statistical Analysis
Results are presented as mean 6 SEM of at least three independent experiments. Differences between groups were analyzed using analysis of variance with SPSS version 15.0 (International Business Machines Corporation, Armonk, New York, USA). Post hoc analysis was used if the analysis of variance was significant. A value of P <0.05 was considered statistically significant.
RESULTS
Preparation and Bioinformatics Analysis for Recombinant MPAPO
The DNA fragment encoding 29 amino acids of MPAPO was directly ligated to a gel-purified NdeI/SapI-digested pKYB-MCS vector (New England Biolabs, Ipswich, MA, USA) to yield the recombinant expression plasmid pKY-MPAPO (Figs. 1A, 1B) . The fusion proteins comprising MPAPO, intein, and chitinbinding domain (i.e., MPAPO-intein-CBD) were expressed through the recombinant vector pKY-MPAPO in E. coli strain ER2566 and purified using chitin affinity column (New England Biolabs). The cleavage of intein was induced by b-mercaptoethanol and the target peptide, MPAPO, was released. Then the recombinant MPAPO was further purified and prepared by reverse-phase HPLC. Approximately 29.6 mg recombinant MPAPO peptide can be obtained from 1 L Luria-Bertani medium. The prepared MPAPO was analyzed and identified by tricine-SDS-PAGE (Fig. 1C) and ESI-MS (Fig. 1D) . The molecular weight of MPAPO obtained by ESI-MS was 3405.0 Da, which was consistent with the theoretical value. The purity of prepared MPAPO was over 96% by the analytical HPLC determination method (Fig. 1E) .
PAC1 receptor belongs to class II 7-transmembrane domain G protein-coupled receptor family (GPCRs). The structure of PAC1 receptor comprises extracellular, transmembrane, and intracellular domain, and PACAP binds to the extracellular domain. The three-dimensional structure of PAC1 receptor was modeled through homology modeling (Fig. 1F) . Binding studies between PAC1 receptor and MPAPO or PACAP27 were conducted by using protein-protein docking software including ZDOCK and RDOCK protocol (Fig. 1G) . Data analysis shows that the binding energy between MPAPO and PAC1 is À91 kCal/mol, which is lower than that of PACAP27 for PAC1, À80 kCal/mol. Compared with PACAP27, MPAPO may have higher affinity and selectivity for PAC1 receptor.
MPAPO Has Higher Stability and Selectively
Activates PAC1 Receptor With Higher Potency and Bioactivity Than Wild PACAP27
The stability of PACAP, VIP, and the recombinant MPAPO was measured at 378C in sodium phosphate buffer (20 mM, pH 8.0) containing 150 mM sodium chloride. After incubation for 4 weeks at 378C, the main peptide peaks for PACAP27, PACAP38, and VIP were remarkably diminished and the slower-migrating peak emerged, probably as a result of peptide degradation. On the other hand, MPAPO exhibited dramatic improvement in stability, losing only 6.7% of the main peak. The stability was increased approximately 31-fold compared with that of PACAP27, PACAP38, and VIP in vitro (Fig. 2A) . (Fig. 2B) . In contrast, the IC50 for VIP(1-7)/GRF (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , an established human VPAC1-specific agonist, for human PAC1 was more than 20 mM. These results showed that MPAPO could competitively displace [
125 I]PA-CAP27 by binding to human PAC1 receptor in PAC1-CHO cells and the IC50 of MPAPO was significantly lower than that of wild PACAP27 and VIP.
The accumulation of cAMP in human PACAP receptortransfected cells (PAC1-CHO, VPAC1-CHO, and VPAC2-CHO) was used as an index of the agonist activity. MPAPO was a potent agonist for the PAC1 with a half-maximal stimulatory concentration (EC50) of 0.21 nM. However, the receptor potency of MPAPO for human VPAC1 (EC50 of 28.9 nM) and VPAC2 (EC50 of 33.7 nM) was only 1/138 and 1/161 of that for human PAC1, respectively. Compared with MPAPO, the EC50 for PACAP27 for human PAC1, VPAC1, and VPAC2 receptor was 0.59, 1.08, and 1.19 nM, respectively (Fig. 2C) . These results showed that MPAPO was a PAC1-specific agonist with high potency and bioactivity (Fig. 2D) , and receptor potency of MPAPO was significantly higher than that of wild PACAP.
MPAPO Can Quickly Perform Corneal Epithelial Wound Closure and Affect Trauma-Related Protein Expression in C57BL/6 Mice
After the C57BL/6 mice with central corneal wound were treated with sterile NS (vehicle), rb-bFGF, PACAP27, and MPAPO, corneal epithelial cells were stained with fluorescein sodium at different time points. The results showed that the injured area stained yellow-green was continuously and significantly decreased over time in MPAPO-treated mice. At 12 hours after the first administration, the repair rate of the injured corneas reached 49.58% in MPAPO-treated mice; however, the repair rate was only 9.76%, 36.75%, and 38.79% in NS-, rb-bFGF-, and PACAP27-treated mice, respectively. MPAPO carried out a complete wound closure but not NS, rb-bFGF, and PACAP27 at 30 hours after the first administration (Figs. 3A, 3B) .
Expression of trauma-related protein such as NGF, FN, TGFb, ICAM-1, and VEGF was determined by ELISA at different time points after the first administration. The results showed that, compared with normal mice and NS-treated mice, the expression level of NGF, TGF-b, and FN, three proteins conducive to wound repair, was significantly higher in PACAP27-and MPAPO-treated mice cornea and reached the maximum level at 12, 24, and 24 hours, respectively, after the first administration (Fig. 3C) .
Expression of ICAM-1, associated with angiogenesis and inflammation, in the normal cornea is quite low. But ICAM-1 expression was significantly increased at each tested time point in NS-treated mice, while MPAPO and PACAP27 could significantly decrease the expression of ICAM-1, and the effect of MPAPO was significantly higher than that of PACAP27 (Fig. 3C) . Expression of VEGF, a cytokine potently promoting CNV, was increased after corneal epithelial wound. Compared with NS-and PACAP27-treated mice, the VEGF expression level was significantly decreased within 30 hours after the first administration in MPAPO-treated mice, reaching the minimum at 30 hours; it then tended toward the normal level at 36 hours (Fig. 3C) .
MPAPO Can Improve Lacrimal Gland Secretion and Inhibit Corneal Neovascularization in Japanese White Rabbits
The Japanese white rabbits were treated with NS and 0.2, 0.5, and 1 nM MPAPO or PACAP27 for 10, 30, 60, and 120 minutes; then lacrimal fluids were collected within 5 minutes after administration, and the lacrimal fluid secretion amounts and lacrimal protein secretion rate were determined. The results showed that MPAPO could significantly increase the lacrimal fluid secretion amount in a dose-dependent manner (Fig. 4A) . In rabbits receiving 1 nM MPAPO for 60 minutes, the lacrimal fluid secretion amount was largest and was 222.9% and 57.8% higher than that for NS and PACAP27 (Fig. 4A) , respectively. Furthermore, the total protein concentration in the lacrimal fluids was also significantly increased over time in MPAPOtreated rabbits. The protein-increasing effects of MPAPO were observed as early as 10 minutes after administration, and the lacrimal protein secretion rate reaching maximum in 0.5 nM MPAPO-treated rabbits at 30 minutes after administration was, respectively, 81.7% and 32.6% higher than that in NS-and PACAP27-treated rabbits (Fig. 4B) . These results showed that MPAPO can significantly improve lacrimal gland secretion, and the increase of lacrimal protein may efficiently ameliorate dry eye induced by injury.
The CNV in NS-, MPAPO-, PACAP27-, and rb-bFGF-treated eyes with central corneal alkali burn was examined on day 7 and 14 after administration. The differences in CNV between MPAPO-and NS-treated rabbits were evident on days 7 and 14, with most of the control eyes showing CNV invading the central cornea and not the MPAPO-treated eyes. The eye number with CNV in MPAPO-treated eyes was 6% (3 of 50) on day 7 and 10% (5 of 50) on day 14, whereas it was 18% and 48% for NS, 12% and 38% for rb-bFGF, and 10% and 30% for PACAP27 on day 7 and 14, respectively ( Table 1) . Areas of CNV in MPAPO-treated eyes were 11.5 6 1.8 mm 2 on day 7 and 12.2 6 1.9 mm 2 on day 14, values that were significantly lower than those in NS-, PACAP27-, and rb-bFGF-treated eyes, and CNV inhibition of MPAPO reached 66.8% on day 7 and 71.2% on day 14, values that were obviously higher than for rb-bFGF and PACAP27 (Table 1) . These results showed that MPAPO can significantly inhibit CNV induced by alkali burn, and the effect was stronger than for rb-bFGF and PACAP27.
MPAPO Significantly Promotes Mouse Corneal Epithelial Cell Proliferation
The normal mouse corneal epithelial cells were treated with PBS and 0.1, 0.2, 0.5, 1, and 5 nM MPAPO or PACAP27 for 24 hours (PBS was used for control), and the cell proliferation rates were measured by MTT method. The results demonstrated that MPAPO can promote normal mouse corneal epithelial cell proliferation below 1 nM in a dose-dependent manner, and the proliferation rate of cells treated with 1 nM MPAPO was up to 70%, which was obviously higher than that for PACAP27 (Fig. 5A) .
The normal mouse corneal epithelial cells were treated with various concentrations of hydrogen peroxide (H 2 O 2 ) for 10 minutes, 30 minutes, and 1, 6, and 12 hours, and the cell survival rates under different injury conditions were calculated. The results showed that the survival rate was approximately 50% when the cells were treated with 200 lM H 2 O 2 for 10 minutes (Fig. 5B) . The H 2 O 2 -injured corneal epithelial cell model was established with this condition and was treated with PBS or 0.1, 0.2, 0.5, 1, and 5 nM MPAPO or PACAP27 for 24 hours. The MTT assay results showed that MPAPO can significantly promote cell proliferation from 0.1 to 1 nM in a dose-dependent manner, and the cell proliferation rate reached approximately 40% for 1 nM MPAPO-treated cells (Fig. 5C ). In contrast, the cell proliferation-promoting effects disappeared in normal or H 2 O 2 -injured mouse corneal epithelial cells preincubated with 100 nM DMax, a PAC1 receptor antagonist, before 1 nM MPAPO or PACAP27 treatment (Figs. 5A, 5C ).
MPAPO Can Significantly Increase Synapse Formation of Trigeminal Ganglion Cells
The trigeminal ganglion cells were separated from C57BL/6 mice and cultured. Then the cells were purified with serumfree medium. The trigeminal ganglion cells were harvested on day 13 and identified using neuron-specific enolase (NSE) as a label with flow cytometry; the amount of NSE-positive cells reached 98.40% (Fig. 5D) . The mouse trigeminal ganglion cells were treated with 0.1 and 1 nM MPAPO or PACAP27 for 48 hours, and the NF-200 immunofluorescence assay results showed that MPAPO can significantly promote synapse growth in mouse trigeminal ganglion cells in a dose-effect manner (Fig. 6A) . The immunofluorescence quantitative analysis for NF-200 showed that the fluorescence intensity in cells treated with 0.1 and 1 nM MPAPO was 1.56-and 2.09-fold that for PACAP27, respectively (Fig. 6B) , whereas the fluorescence intensity was significantly reduced in DMax-treated cells before 1 nM MPAPO treatment. The results demonstrated that MPAPO can significantly promote synapse growth in mouse trigeminal ganglion cells through PAC1 activation, and the biological effects were significantly higher than those for PACAP27.
MPAPO-Promoted Corneal Nerve Injury Repair May Relate to MAPK Signaling Pathway
Mouse normal and H 2 O 2 -injured trigeminal ganglion cells were respectively treated with PBS or 1 nM MPAPO for 48 hours, and the cell gene expression was analyzed with GeneChip (Affymetrix, Santa Clara, CA, USA). The results showed that after MPAPO administration, some gene expressions in several signaling pathways had significant difference. The number of differential expression genes reached 16 in mitogen-activated protein kinases (MAPK) signaling pathway (Table 2) , a key signal transduction pathway associated with trauma. Furthermore, Western blot assay results demonstrated that MPAPO could significantly increase expression of Akt, p-Akt (Thr308), Erk1/2, and p-Erk1/2 in normal trigeminal ganglion cells (Fig.  7A) . In the H 2 O 2 -injured trigeminal ganglion cells, even without MPAPO treatment, expression levels of p-Erk1/2 and p-Akt (Thr308) were higher than in normal cells, which may relate to the emergency reaction after injury. The expression of p-Akt (Thr308) and p-Erk1/2 was 1.28-fold and 0.75-fold higher in MPAPO-treated cells than PBS-treated controls, whereas there was only a 0.83-and 0.44-fold increase in the expression of pAkt (Thr308) and p-Erk1/2 in PACAP27-treated cells, respectively-values significantly smaller than in MPAPO-treated cells (Fig. 7B ). These expression or phosphorylation level increases could further activate the downstream signal transduction, which could effectively promote synapse growth and proliferation of neural cells, thus significantly facilitating the functional recovery of corneal and trigeminal nerve after injury.
DISCUSSION
The cornea is a vital component of the eye because it provides approximately 70% of the refraction and focusing of incoming light. Unlike most tissues in vivo, the cornea contains no blood vessels to nourish or protect it against infection. Instead, the cornea receives its nourishment from tears and aqueous humor, furthermore supplied by the terminal branches of the ophthalmic division of the trigeminal nerve. It was found that exogenous protein was taken up in axonal branches in the ophthalmic nerve and transported back to the trigeminal ganglion as has been suggested for certain viral infections. 27 When corneal injury occurs, many terminal branches of the sensory nerves are cut or damaged; thus the cornea's main function and transparency are severely damaged. Corneal injury can also induce dry eye, and in turn dry eye may aggravate postinjury neovascularization and inflammation. 28 Several therapeutics against corneal injury have been explored; and some cytokines, such as basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), keratinocyte growth factor, vascular endothelial factor (VEGF), and pigment epithelium-derived factor (PEDF), have been found to stimulate corneal epithelial cell migration and wound closure in vivo. [29] [30] [31] However, with bFGF or EGF acting as the main therapeutics, bFGF-or EGF-induced corneal angiogenesis, which is currently untreatable, is a significant side effect. Thus for repair of corneal injury, effectively promoting wound closure, adequate corneal innervation, and neovascularization inhibition is key to restoring normal function.
PAC1, as the specific receptor for PACAP, is widely distributed on the membranes of target cells such as corneal epithelial cells and trigeminal ganglion cells; PACAP thereby plays biological roles such as promoting cell proliferation, growth, development, differentiation, and injury repair, mainly via PAC1 receptor activating the cAMP-dependent protein kinase (PKA) signal pathway and phosphatidylinositol signal transduction pathway. 33, 34 In addition, PACAP has been reported to have potential anti-inflammatory activity that could be beneficial in the setting of corneal injury. 35 However, the first two N-terminal amino acids of wild PACAP and some of its derivates are H-S-, which is sensitive recognition and cleavage site of the DPP4, and it has been confirmed that DPP4 is widely distributed in ocular tissues, especially corneal epithelium and endothelium. 36 The PACAP segment that lost the N-terminal sequence H-S-converted PACAP from an agonist of PAC1 to an antagonist with low binding affinity. Furthermore, the peptides were poorly stable in aqueous solution and easily degradable; thereby their therapeutic application has been hampered by the short half-life and limited bioavailability in vivo. 15 In the current work, compared with wild PACAP27, the new recombinant MPAPO with four mutations was generated using gene recombination technique. A methionine was additionally added to the N-terminus of MPAPO in order to block the Nterminus and prevent loss of the sequence H-S-susceptible to enzyme digestion by DPP4. The M17L mutation was introduced in an effort to eliminate oxidation, which was present in wild PACAP, contributing to destabilization in vivo. 18 Bioinformatics analysis showed that the L27K mutation and addition of a lysine to the C-terminus would contribute to the higher affinity or specificity of MPAPO for PAC1 compared to wild PACAP (data not shown). Consistent with this, the experimental results showed that MPAPO was a PAC1-specific agonist with higher stability and receptor potency than wild PACAP. In the mouse model with corneal injury, MPAPO can quickly perform corneal epithelial wound closure, and the repair effect was stronger than that for wild PACAP27 and rb-bFGF, an anti-corneal wound clinical drug. MPAPO can also significantly increase the expression of NGF, TGF-b, and FN while inhibiting high expression of ICAM-1 and VEGF after corneal injury. Nerve growth factor can promote corneal epithelial cell proliferation and migration and accelerate corneal wound healing by stimulating the release of various neuropeptides or growth factors; in addition, NGF plays an important role in sensory neuron survival as a neurotrophic factor. 37 Fibronectin is not only the marker protein for reactive wound repairing/healing, but also an extracellular protein for enhancing nerve repair. Transforming growth factor-b can increase the expression of extracellular matrix genes, such as FN, and various collagens and proteinase inhibitors. 38 However, there was little or no ICAM-1 expression in the normal cornea 39 ; abnormally high expression occurred after corneal injury, thereby inducing the inflammatory and VEGF-dependent CNV. 40 Corneal neovascularization can be significantly decreased by specifically inhibiting VEGF in mouse and rat. 41, 42 Accompanying corneal and nerve terminal branch injury, corneal sensations are decreased; moreover, injury-induced nutritional and metabolic disorders may result in dry eye. It has been demonstrated that PACAP27 can enhance lacrimal gland secreting proteins and restore the lacrimal reflex. 43 The recombinant MPAPO can significantly increase lacrimal gland secretion in rabbits; thus MPAPO can not only promote corneal injury repair but also efficiently ameliorate injury-induced dry eye.
Some studies have confirmed that PAC1 receptor plays key roles in mediating the development and function of the nervous systems. 7, 44 But there is yet no report on the signal transduction mechanism of trigeminal ganglion cell injury repair. This work showed that the genes of MAPK signal pathway molecules were significantly differentially expressed in MPAPO-treated injured mouse trigeminal ganglion cells. Consistent with the GeneChip assay, expression of phosphorylated Akt and Erk1/2 in the MPAPO-treated injured mouse trigeminal ganglion cells was significantly upregulated (Western blot test); this can efficiently promote the survival and differentiation of the neurons, as well as nerve injury repair through the PI3K-Akt, Erk, or p38MAPK signal transduction pathways.
The use of proteins and peptides as human therapeutics has increased rapidly in recent years. 45 Peptides are considered viable therapeutic agents because of their superior specificity compared to small molecules and their smaller size relative to antibodies. 46 In addition, we have optimized the expression and preparation conditions for MPAPO so that the MPAPO yield can reach 30 mg/L (Luria-Bertani culture), and purity can reach more than 96%. As compared with the commonly used chemically synthesized PACAP and derivates, the cost can be reduced by approximately 60%.
In summary, our study provides the new recombinant PACAP-derived peptide MPAPO, with higher stability, which exhibits potent effects in promoting corneal wound repair and lacrimal secretion without neovascularization via selective activation of PAC1 receptor. Currently, clinical therapeutics with few side effects for corneal injury are rare, so the recombinant MPAPO has potential to be developed into an external therapeutic against corneal injury or dry eye. Gene analysis was performed by using Kyoto Encyclopedia of Genes and Genomes (KEGG, Kyoto University, Kyoto, Japan). 
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